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Abstract
Within current oncology practice several genomic applications are being use to inform treatment 
decisions with molecularly targeted therapies in breast, lung, colorectal, melanoma and other 
cancers. This commentary introduces a conceptual framework connecting the full spectrum of 
biomedical research disciplines, including fundamental laboratory research, clinical trials, and 
observational studies in the translation of genomic applications into clinical practice. The 
conceptual framework illustrates the contribution that well-designed observational 
epidemiological studies provide to the successful translation of these applications, and 
characterizes the role observational epidemiology plays in driving the dynamic and iterative 
bench-to-bedside, and bedside-to-bench translation continuum. We also discuss how the principles 
of this conceptual model, emphasizing integration of multidisciplinary research, can be applied to 
the evolving paradigm in “precision oncology” focusing on multiplex tumor sequencing, and we 
identify opportunities for observational studies to contribute to the successful and efficient 
translation of this paradigm.
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Introduction
Translational research generally refers to the application of scientific discoveries to develop 
new approaches to prevention, early detection, diagnosis, and treatment of disease in clinical 
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and public health practice, ultimately leading to effective health policy and improved health 
outcomes.(1) This paradigm has been called bench-to-bedside and has received increasing 
priority in recent years by programs such as National Institutes of Health's Clinical and 
Translational Science Award program.(2) To clarify the role of epidemiology in 
translational research, Khoury and colleagues presented an expanded framework for the 
concept of translational epidemiology as a fundamental science for moving laboratory 
discoveries (e.g., molecular and computational biology, molecular pathology, “-omics” 
science, pharmacology, and radiobiology, etc.) into clinical and public health practice.(3) In 
this framework, translational epidemiology, encompassing observational, experimental, and 
theoretical epidemiological methods, links laboratory and clinical aspects with population 
research. Application of epidemiologic principles in population-based scientific 
investigations, including the development of a hypothesis, defining the population, 
comparisons and outcomes, study design and conduct, and data analysis and interpretation, 
is necessary to understand the natural history of disease, identify risk or protective factors, 
and provide evidence for the utility of novel interventions. This can, in turn, influence 
further laboratory, clinical, and population-based research, policy and practice.
The purpose of this article is to demonstrate the unique opportunities that observational 
epidemiology has to offer to advance cancer precision and genomic medicine, recently 
referred to as “precision oncology”.(4) Precision oncology uses broad-spectrum molecular 
and systems biology techniques to analyze an individual patient's cancer at the molecular 
level and then develop targeted treatments in combination with important contextual features 
(clinical and treatment history, comorbidities, preferences, and inherited genetic 
susceptibilities related to potential drug interactions and toxicities) to optimize a patient's 
response. In this commentary we first introduce a conceptual framework integrating 
laboratory sciences, clinical trials, and observational studies (Figure 1). In so doing we 
highlight translational epidemiology as a bidirectional process, where new knowledge 
gained from the bedside (i.e. the population) is translated back to the benches of laboratory 
science. We will use this iterative concept to provide examples of how study designs, 
hypotheses, and findings offered by observational epidemiologic studies can play important 
roles in driving translational research that advances precision oncology, leading in some 
cases to successful clinical implementation. Finally, we discuss how observational 
epidemiology can contribute to an emerging paradigm, incorporating next-generation tumor 
sequencing technology into clinical oncology practice.
Observational Epidemiology in Precision Oncology
Due to the long latency period of cancer development, observational study designs (Table 1) 
have, by necessity, played an important role in the translation (i.e., development, validation 
and evaluation) of effective clinical and public health interventions, especially for cancer 
screening, early detection and prevention. The proliferation of high throughput “-omic” 
technologies provides tremendous opportunities for observational studies to efficiently 
develop and evaluate many possible gene-treatment hypotheses applied to cancer treatment 
and precision oncology. To date, the translation of applications for precision oncology has 
largely emphasized the laboratory as the starting point in the bench-to-bedside translational 
continuum. The discovery of biomarkers able to predict treatment response and the 
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development of molecularly targeted therapies is often portrayed as following a linear, 
unidirectional process culminating with evaluation in a prospective randomized controlled 
trial (RCT).(5) While this might be the prototypical translational model, even this form of 
translational research is iterative with feedback loops driven by observational epidemiology 
during the discovery, validation, evaluation and implementation steps.(3) The use of 
epidemiology and the strengths of observational studies to inform precision oncology have 
not been generally discussed.
The epidemiologic principles for developing a precision oncology application require 
explicit description of the population of interest (sociodemographic, clinical, genomic, and 
treatment characteristics), clearly defining both the genomic and treatment comparisons 
being made, and capturing the clinical outcomes used to evaluate such comparisons. 
Attention to these principles, especially the comparisons being made, will help distinguish 
prognostic factors (predict course of disease regardless of treatment) from predictive factors 
(able to predict treatment response and outcomes), and will provide a foundation to facilitate 
further translational research.(6) In the development of genomic markers as prognostic and 
predictive factors, strengths of observational studies include access to diverse patient 
profiles and cancer types otherwise not necessarily eligible for RCTs designed to address 
similar questions. Observational studies also allow the examination of large sample sets to 
interrogate the interaction between a discrete genomic marker and binary treatment variable 
to predict outcomes. However, observational epidemiology has its limitations in establishing 
causal effects and is vulnerable to non-causal explanations observed in gene-treatment 
interactions (e.g. bias and confounding). For example, variation in treatment allocation, 
dose, and frequency and uneven distribution of risk factors associated with outcomes of 
interest between treated and untreated groups may allow for potential confounding and 
selection bias.(7)
In order to overcome such limitations, investigators seeking a more robust measure of effect 
rely on experimental epidemiology methods, which include the randomized controlled trial 
(RCT). Many of the inherent qualities of conventional RCTs including randomized 
treatment assignments, pre-specified participant eligibility criteria and treatment regimens, 
rigorous participant follow-up and data collection, and masking participants and trial 
investigators, substantiates RCTs as the highest levels of evidence to evaluate the efficacy of 
a clinical or public health intervention. Given their inherent strengths, RCTs have 
traditionally played a prominent role within the bench-to-bedside continuum. However, 
conventional RCTs have limited generalizability due to the highly selected patient 
populations enrolled in trials, and may not efficiently recruit the large number of participants 
needed to test multiple gene-treatment interactions.
Conceptual Model
To fully realize the potential of precision oncology, it is essential to integrate laboratory 
discoveries with evidence-based systematic evaluations in both a well-defined clinical 
setting (e.g., proof-of-principle efficacy studies) and in large heterogeneous populations 
(e.g., effectiveness study in large populations). This can be done most efficiently by taking 
advantage of the complementary aspects of laboratory research, clinical trials and 
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observational studies that employ a range of scientific methods to establish a portfolio of 
evidence. Figure 1 presents our conceptual model, which illustrates the interdependent 
continuum forming these connections.
The research and development of new cancer therapeutics has historically followed an 
agnostic approach in pre-clinical research using in vitro screening of a vast array of 
molecules followed by animal testing and early phase clinical trials designed to establish a 
safe and effective dose. Variation in treatment response may be due in part to the 
heterogeneity of participants based on genetic and other factors. A large proportion of 
participants with no or suboptimal therapeutic response who share a common molecular 
profile may produce an overall non-significant result for a therapy that is otherwise 
promising in a different patient subgroup. More recently, development of cancer 
therapeutics has followed a hypothesis-driven approach focusing on the mechanisms of 
action to guide drug development. Knowledge of inter-individual variation as well as 
variation in the molecular pathways driving tumorigenesis, observed in clinical research, is 
fed back into the laboratory as unique genomic and/or molecular targets for future drug 
development.(4,8,9) Alternatively, in vitro screening of a library of approved therapeutics 
used in clinical practice for a variety of non-cancer related indications for growth inhibition 
could provide new hypotheses for cancer prevention and treatment. Such hypotheses can be 
evaluated in existing observational cohort studies with long-term follow-up for a large 
number of participants and many possible cancer outcomes, eventually moving to clinical 
trials.(10,11)
While clinical trials are the primary source of information on the utility of therapeutic 
agents, for a large number of rare cancers, and for certain population subgroups, clinical trial 
data are often unavailable to assess the utility of a treatment in a population of interest. In 
addition, older established anticancer drugs were typically assessed at a time when 
biological specimens were not collected within the clinical trials that established their 
clinical utility. In such instances, observational clinical studies can provide information on 
drug effectiveness in particular sub-populations as well as the incidence of rare acute 
adverse events and long-term toxicity in particular risk subgroups. This concept can also be 
extended to non-pharmacologic and technology-driven therapies, such as radiation therapy. 
This is particularly important for patient sub-groups with particular genomic profiles as well 
as patients typically not represented in trials such as the elderly and those with 
comorbidities. Discoveries arising from post-marketing surveillance and observational 
studies can guide researchers in cultivating new hypotheses that can inform basic molecular 
research. Using this feedback loop, new prospective clinical studies using innovative trial 
designs (e.g., FOCUS and Lung-MAP trials) can be initiated that incorporate genomic 
components into their design to establish both the utility and safety of precision therapy 
based on a person's genomic and clinical risk profile.
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Examples of Observational Epidemiology Driving Translation of Precision 
Oncology
Discovery of a Prognostic Marker to Advance Drug Development
There is perhaps no better example of using observational epidemiologic clinical research to 
translate laboratory discoveries into improved population health outcomes than the 
development of trastuzumab for treating HER2/neu positive breast cancer. In the mid 1980's 
several independent laboratory investigations provided evidence of the biological 
mechanisms by which HER2/neu (human epidermal growth factor 2) promotes cancer 
proliferation, and demonstrated increased levels of this marker in a number of different 
tumor types.(12-14) Two key observational studies in women with lymph-node positive 
breast cancer showed that increased HER2/neu expression was associated with lower disease 
free survival and overall survival compared with normal HER2/neu expression.(15,16) The 
contributions from observational epidemiological studies, demonstrating the prognostic 
importance of HER2/neu overexpression (15-17) provided sufficient evidence to drive the 
development of the first ever molecularly targeted cancer therapy – trastuzumab, a 
monoclonal antibody targeting tumor cells expressing HER2/neu. Eventually a Phase III 
trial investigating the efficacy of trastuzumab in participants with HER2/neu amplification 
confirmed the ability of HER2/neu expression to predict treatment outcomes with 
trastuzumab.(18) During this period, additional observational studies helped to establish the 
proportion of patients carrying this molecular change in their breast cancer tumors, leading 
to a clearer understanding of the potential clinical impact and costs associated with this new 
biomarker-driven therapy that shaped subsequent health care policy.(19) The progression 
through the translational continuum using observational epidemiology methods to build on 
prior knowledge (laboratory and observational) to inform clinical trial design highlights the 
reciprocal nature of translational epidemiology (Figure 1).
Marker Discovery and Confirmation of Predictive Value
Since the introduction of anti-EGFR therapy, additional molecular discoveries have led to a 
greater understanding of the genes involved in the EGFR pathway in colorectal 
carcinogenesis. After cetuximab (in 2006) and panitumumab (in 2007) received approval by 
the FDA for treatment of metastatic colorectal cancer, investigators began to wonder if 
treatment outcomes observed in the trials were mediated by variation in EGFR expression. 
Once it became clear that EGFR expression did not predict treatment outcomes with either 
EGFR-targeted therapy, there was great interest in whether mutations in the downstream 
coding genes in the EGFR pathway (i.e., KRAS, BRAF, and PI3KCA) could influence 
outcomes with anti-EGFR therapy.(20) Based on the evidence from two observational 
clinical studies in metastatic colorectal cancer patients undergoing cetuximab therapy 
investigators were able to show that individuals whose tumors had a KRAS mutation did not 
achieve the same clinical response compared with those with wild-type KRAS tumors.
(21,22) Further hypothesis-driven “prospective-retrospective” analyses, comparing KRAS 
wild-type with KRAS-mutant tumors in archived tumor samples from the RCTs that 
investigated the efficacy and safety of cetuximab and panitumumab, confirmed the ability of 
KRAS mutation status to predict treatment outcomes.(23,24) Leveraging knowledge of the 
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molecular landscape of the EGFR pathway with the observational data, researchers were 
able to demonstrate the prognostic characteristics of KRAS, and when combined with the 
retrospective analyses of trial data validating the gene-treatment interaction (i.e., prediction), 
developed and validated a new hypothesis of the molecular mechanism mediating treatment 
response to EGFR-targeted therapy.
Hypothesis Generation and Discovery of Pharmacokinetic Mechanisms
Despite the variability in response to remission maintenance therapy with 6-mercaptopurine 
(6-MP) in children with acute lymphoblastic leukemia (ALL), the exact mechanism by 
which 6-MP is able to maintain remission was not immediately known, nor were the causes 
of serious treatment-related toxicities. In a series of observational epidemiological 
investigations, researchers linked genetic variability in thiopurinemethyltransferase (TPMT), 
an important enzyme involved in 6-MP metabolism (25) to levels of 6-thioguanine 
nucleotides (6-TGN), the active metabolites of 6-MP.(26,27) Additional observational 
studies reported the association between 6-TGN and 6-MP treatment related toxicity (i.e. 
myelosuppression).(28,29) The sequential accumulation of observational epidemiological 
evidence including: 1) the candidate gene analysis; 2) the correlation between 6-TGN and 
toxicity; and 3) the negative correlation between TPMT activity and 6-TGN concentration, 
allowed researchers to develop a chain of evidence linking the ability of TMPT to predict 6-
MP treatment-related toxicity. Despite the absence of direct evidence of the association 
between TPTM genotype and 6-MP related toxicities from RCTs, the chain of evidence 
influenced the Clinical Pharmacogenetics Implementation Consortium Guidelines to 
advocate for customized 6-MP dosing based on TMPT genotype to limit potential toxicities.
(30)
Opportunities and challenges for observational epidemiology in the era of 
multiplex tumor evaluations
Knowledge gained from high throughput interrogations of genomic alterations has led to the 
characterization of dynamic pathways and driver mutations associated with tumorigenesis,
(4,31) and has revealed great molecular diversity within histologically similar cancer types. 
For the first time in the post-GWA era, genomic information has the potential to become 
integrated into everyday clinical decision-making. At the vanguard of genomic medicine the 
current precision oncology paradigm has the technological capabilities to address the single 
most important question in biomedical research – what is the best treatment for each 
individual?
Much of the evidence driving the paradigm shift is rooted in the scientific theory of cancer 
biology (i.e. mechanistic pathways and driver mutations) with supporting evidence from the 
traditional single-marker-single-drug applications (e.g. companion diagnostics). A series of 
hypothesis-driven and “discovery” clinical trials, forging a consilience between genomic 
alterations in key pathways and the molecular targets of therapeutics in development, 
individually, may validate a single a priori gene-treatment interaction hypothesis in a small 
subgroup of molecularly defined patients. However, there remains a need to consider further 
observational study designs in order to investigate a growing number of molecularly 
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targeted therapies in an ever-shrinking pool of patients with molecularly defined tumor 
subtypes, and in the setting where more and more tumors are found to contain multiple 
targetable molecular aberrations, many of which will require treatment with combinations of 
drugs.(32)
The systematic accumulation of individual patient experiences in the real-time practice of 
precision oncology possesses the necessary elements to advance evidence-based practice 
while simultaneously driving further translational research. Integrating epidemiologic 
principles in this type of active-learning system, anchored by observational studies, will 
allow for efficient knowledge integration through rapid synthesis and evaluation of precision 
oncology while ensuring continuous investigation, discovery, and evidence implementation.
(33,34) Several contemporary examples of an active learning system that collect 
comprehensive genomic and treatment data from unique “N of 1” encounters include 
CancerLinQ(35) and CancerCommons.(36) While these model systems rely on different 
architectural principles in the construction of an active-learning knowledge base (complete 
electronic health records from participating institutions versus donated clinical data from 
individual patients), they are designed to provide a reliable evidence base, generated across 
diverse institutional and health systems environments, to be used in real-time clinical 
decision making.(37)
The development of an active-learning system potentially provides a robust research 
infrastructure for national outcome-based cohorts and consortiums (histology-based or 
histology-independent) as well as cancer genome databases, like My Cancer Genome, that 
can efficiently integrate findings into clinical practice while also generating new gene-
treatment interaction hypotheses. The Lung Cancer Mutation Consortium (LCMC) recently 
published results from a multi-institution observational study that used multiplex genotyping 
methods to systematically identify 10 driver mutations in 1007 participants with lung 
adenocarcinoma and to use this information to guide treatment decisions.(38) The large 
effects observed in smaller, observational investigations of therapies targeting specific 
genomic alterations in molecularly homogeneous populations may provide sufficient 
evidence of clinical validity and utility otherwise not readily available from traditional RCTs 
and may provide the groundwork for clinical trials to validate the treatment effects of 
promising targeted therapies.(4,39)
As a growing evidence-base emerges from the everyday practice of precision oncology it is 
important to maintain the proper epidemiological perspective when designing future 
experimental trials to test the gene-treatment hypotheses that arise from an active-learning 
environment. The introduction of an active-learning system for precision oncology within 
our conceptual model illustrates where observational studies can add more certainty to the 
underlying treatment hypotheses while simultaneously generating evidence of clinical 
validity and utility of the potential benefits and harms in precision oncology. The dynamic 
process of evaluating rational combinations of targeted therapies through an active-learning 
system will improve our understanding of cancer biology, enhance our understanding of 
tumor evolution and the emergence of drug-resistance, and contribute to mechanistic 
approaches to drug development. In doing so, the bidirectional flow of information between 
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laboratory science, clinical trials, and observational studies can be efficiently linked with 
clinical and population outcomes across cancer types.
Conclusion
We have demonstrated the unique opportunities that observational epidemiology has to offer 
to advance the application of precision oncology. Study designs, hypotheses, and inferences 
drawn from observational epidemiology help define the complementary and iterative bench-
to-bedside translation of laboratory science, clinical trials, and observational epidemiology 
(Figure 1). All epidemiologic study designs, including clinical trials, have limitations and 
different designs answer different questions, so an understanding of the advantages and 
limitations of each design at each point within the dynamic translational continuum is 
important. Failure to recognize the context-specific strengths and weaknesses can jeopardize 
the development of a promising application and contribute to slowing the pace of 
translation.
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Figure 1. Conceptual model connecting laboratory science, clinical trials, and observational 
epidemiologic research to advance precision oncology
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Table 1
Common observational study designs used in translational epidemiology
Study design Description Inferences
Cohort Longitudinal study following a group of people representing a 
defined characteristic or experience over time
Identify risk factors for disease or outcome of 
interests (i.e. survival)
Can identify both prognostic factors1 and 
predictive markers2 (i.e. gene-drug interaction)
Case-cohort Compare all incident cases from existing longitudinal study 
(e.g. cohort) to random selection of non-cases (e.g. controls) 
from same cohort.
Identify prognostic factors1 associated with 
outcome of interest
Nested case-control Controls from existing longitudinal study (e.g. cohort) matched 
to all incident cases from the same cohort on certain factors (i.e. 
age, gender, race, etc.)
Identify prognostic factors1 associated with 
outcome of interest
Case-control Selection of cases and controls based on disease status Identify factors associated with outcome used 
to select cases and controls
Case-series (e.g. clinical 
series)
A group with a common clinical diagnosis and similar exposure 
or treatment history
Identify prognostic factors1 associated with 
clinical outcomes
Case-only All cases selected from a cohort during follow-up (including a 
randomized controlled trial)
Identify predictive markers (i.e. gene-drug 
interaction)2
Cross-sectional Observations made in a representative sample of the larger 
population of interest at one specific point in time
Assess prevalence of risk factors and burden of 
disease at a single point in time
Registry Systematic (often mandated by law) reporting of health 
outcomes (e.g. disease incidence) by clinical and public health 
professionals
Asses temporal trends of disease burden within 
a defined population
1
“A measure correlated with a clinical outcome in the setting of natural history or a standard of care regimen; It is a variable used to estimate the 
risk of or time to clinical outcome”(5)
2
“A measure that identifies patients most likely to be sensitive or resistant to a specific treatment regimen or agent. An effect modifier is 
particularly useful when that measure can be used to identify the subgroup of patients for whom treatment will have a clinically meaningfully 
favorable benefit-to-risk profile”(5)
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